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Abstract
Background: Recently, the 13-valent pneumococcal conjugate vaccine (PCV13) has been recommended for adults. We
analyzed the epidemiology of invasive pneumococcal disease (IPD) in older adults in Spain before PCV13 introduction.
Methodology/Principal Findings: IPD episodes, defined as clinical findings together with an invasive pneumococcal isolate,
were prospectively collected from patients aged over 65 years in three hospitals in Spain from 2007 to 2009. A total of 335
IPD episodes were collected. Pneumonia was the main clinical syndrome, while chronic obstructive pulmonary disease,
diabetes mellitus and cancer were the main underlying diseases. Pneumococcal isolates were serotyped and the molecular
typing was performed by PFGE/MLST. PCV13 serotypes accounted for 59.3% of isolates, the most prevalent being serotypes
19A (15.1%), 3 (9.6%), 7F (7.5%), 14 (6.9%) and 1 (5.4%). The most frequent non-PCV13 serotypes were serotypes 16F (4.5%),
22F (3.6%), 24F (3.3%) and 6C (2.1%). The most common genotypes were CC230 (8.5%, serotypes 19A and 24F), CC156
(8.2%, serotypes 9V and 14), ST191 (7.9%, serotype 7F), CC260 (6.6%, serotype 3), ST306 (5.2%, serotype 1), CC30 (4.6%,
serotype 16F) and ST433 (3.6%, serotype 22F). Comparing the 335 IPD isolates to 174 invasive pneumococci collected at the
same hospitals in 1999–2000, PCV7 serotypes decreased (45.4% vs 18.4%,p,0.001), non-PCV7 serotypes included in PCV13
increased (26.4% vs 41.0%,p = 0.001) and two non-PCV13 serotypes increased (serotype 6C 0% vs 2.1%, p = 0.05; serotype
24F 0.6% vs 3.3%, p = 0.04,).
Conclusion: In our older adult population two serotypes (19A and 3) included in PCV13 accounted for about a quarter of
IPD episodes in people $65 years. Non-PCV13 emerging serotypes should be carefully monitored in future surveillance
studies.
Citation: Ardanuy C, Marimo´n JM, Calatayud L, Gime´nez M, Alonso M, et al. (2012) Epidemiology of Invasive Pneumococcal Disease in Older People in Spain
(2007–2009): Implications for Future Vaccination Strategies. PLoS ONE 7(8): e43619. doi:10.1371/journal.pone.0043619
Editor: Herminia de Lencastre, Rockefeller University, United States of America
Received March 7, 2012; Accepted July 26, 2012; Published August 22, 2012
Copyright:  2012 Ardanuy et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by grants from the ‘‘Fondo de Investigaciones Sanitarias’’ (PI081922, PI090104, PI1000127, and PI11/0763), the Basque
Government 2009/111012 and by CIBER de Enfermedades Respiratorias (CIBERES), a project run by the Instituto de Salud Carlos III. The funders had no role in
study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interest exists.
* E-mail: c.ardanuy@bellvitgehospital.cat
Introduction
Streptococcus pneumoniae is a major cause of morbidity and
mortality worldwide, it being responsible for a wide variety of
invasive diseases such as bacteremic pneumonia, septicemia and
meningitis [1]. Children under 2 years of age and adults over 65
are the two most important groups with a higher risk of invasive
pneumococcal disease (IPD). The nasopharynx of children,
especially those attending day-care centers, is usually colonized
by pneumococci, which may spread to adults.
Pneumococci are divided into at least 93 different serotypes, and
some capsular polysaccharides have been used to develop
vaccines. Since the late 1970s adult vaccination has been based
on pneumococcal polysaccharide vaccines (PPV). Currently,
PPV23 is recommended for people over 65 and adults at risk of
IPD [2]. Since PPV23 has low effectiveness against children under
5 (especially those under 18 months), conjugate pneumococcal
vaccines have been developed, with the 7-valent pneumococcal
conjugate vaccine (PCV7) being licensed in 2000 in the US, and
since 2001 in most European countries.
Despite the implementation of PPV23 in older adults no
significant changes in the incidence of IPD, serotype distribution
and penicillin resistance were observed during the 1990s in Spain
[3,4]. The most important change in the 1990s was the increase in
macrolide resistance rates, which was probably associated with the
introduction of long-acting macrolides and the spread of mobile
elements carrying macrolide resistance determinants [3–5].
However, after introduction of PCV7 for children, IPD caused
by PCV7 serotypes, as well as antibiotic resistance rates, decreased
in children in the US and in many other countries [6–10]. This
decrease was also observed in adults, especially those aged over 65,
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due to herd protection [8,10–13]. The surveillance of pneumo-
coccal serotypes/clones in these countries identified the evasion of
vaccine immunity as being due to the increase of non-vaccine
serotypes and clones, as well as to the emergence of new clones
produced by capsular switching events [9–11,14,15].
Two new pneumococcal conjugate vaccines are currently
available for child vaccination and they include 10 (PCV10) and
13 (PCV13) pneumococcal serotypes. The indirect effect of child
vaccination observed in adults, especially those older than 65, has
increased interest worldwide in using these new conjugate vaccines
in adult vaccination. In 2011, PCV13 was approved for adult
vaccination schedules in the US and Europe.
In this study we aimed to analyze the serotype and genotype
composition of invasive pneumococci isolated from older adults
before the introduction of PCV13 in three Spanish hospitals. In
addition, we also compared the current serotype and genotype
distribution to that studied previously (1999–2000) in order to
identify the emerging serotypes/clones that are not included in
PCV13.
Results
A Total of 335 IPD Episodes were Studied in Older Adults
from 2007 to 2009
Table 1 shows the demographic characteristics, source of
strains, clinical syndromes and the main underlying diseases
(2007–2009 vs. 1999–2000). The most important source of strains
was blood cultures, with pneumonia being the main clinical
syndrome. The main underlying diseases were chronic obstructive
pulmonary disease (COPD), diabetes mellitus, cancer and chronic
renal failure.
Table 2 shows the antibiotic susceptibility to 8 antimicrobials of
335 pneumococci collected from invasive disease. Using oral
breakpoints (classical), more than a quarter of the isolates showed
penicillin non-susceptibility and 7.5% showed cefotaxime non-
susceptibility. However, it should be noted that when using current
non-meningeal CLSI breakpoints for parenteral penicillin and
cefotaxime 98.5% of isolates were fully susceptible, which supports
the use of beta-lactams in the treatment of non-meningeal
infections. Although rates of erythromycin, tetracycline and
cotrimoxazol resistance are lower than those reported previously
in Spain, the non-susceptibility rates of these antibiotics remains
above 20% [3,4]. Chloramphenicol and ciprofloxacin showed
good in vitro activity.
Among 332 serotyped pneumococci collected in 2007–2009 the
five most frequent serotypes were: 19A (n = 50, 15.1%), 3 (n = 32,
9.6%), 7F (n = 25, 7.5%), 14 (n = 23 6.9%) and 1 (n = 18, 5.4%).
The proportion of IPD isolates included in PCV7 was 18.4%, with
the proportions being 33.7% in PCV10, 59.3% in PCV13 and
73.8% in PP23V. The most frequent non-PCV13 serotypes were
serotypes 16F (4.5%), 22F (3.6%), 24F (3.3%) and 6C (2.1%).
Table 3 shows the STs associated with major serotypes. Overall,
the most frequent genotypes among IPD isolates from the 2007–
2009 period were CC230 (n = 26, 8.5%), CC156 (n = 25, 8.2%),
ST191 (n = 24, 7.9%), CC260 (n = 20, 6.6%), ST306 (n = 16,
5.2%), CC30 (n = 14, 4.6%) and ST433 (n = 11, 3.6%).
During this period (2007–2009) pneumonia was the most
frequent cause of IPD (n = 269 episodes). Among these cases the
most frequent serotypes were 19A (n = 43, 16.2%), 3 (n = 25,
9.4%), 7F (n = 23, 8.6%) and 14 (n = 20, 7.5%). PCV10 serotypes
accounted for 34.2% of pneumonia isolates and PCV13 for
60.9%. In this period, 21 pneumococci were collected from pleural
fluid and the most frequent serotypes were 1 (n = 3), 3 (n = 3), 19A
(n = 2) and 14 (n = 2).
Among 28 isolates causing meningitis in the 2007–2009 period
the most frequent serotypes were 3 (n = 4), 6C (n = 3), 19A (n = 3),
5 (n = 2), 8 (n = 2), 24F (n = 2), 23A (n = 2) and 23F (n = 2). Using
current CLSI breakpoints for meningitis, no cefotaxime resistance
was detected among these 28 meningeal isolates (MIC range
,0.03–0.5 mg/ml), although 17.8% of them were penicillin
resistant (range 0.12–0.5 mg/ml). The three IPD episodes related
to otomastoiditis were caused by serotypes 3, 14 and 22F.
Four serotypes (19A, n = 22; 14, n = 19; 24F, n = 10; and 9V,
n = 6) accounted for 66.3% of penicillin non-susceptible isolates
(MIC $0.12 mg/ml), the most frequent CC being CC230 (n = 26,
31.7%) and CC156 (n = 25, 30.5%). The main serotypes among
cefotaxime non-susceptible isolates were 14 (n = 11), 19A (n = 8)
and 9V (n = 5), whereas a single clonal complex CC156 (n = 17)
accounted for 68% of these isolates.
Serotypes 19A (n = 21), 24F (n = 10) and 16F (n = 8) accounted
for 49.5% of macrolide-resistant strains, which were related to
CC230 (n = 19), CC30 (n = 7) and CC63 (n = 6) and accounted for
41.9% of strains. These macrolide-resistant serotypes and clones
were associated with clindamycin and tetracycline resistance,
probably due to the presence of transposons of the Tn916-family,
which carry macrolide- and tetracycline-resistant genes [5].
Since pneumococci were collected from three hospitals located
in two Spanish regions the serotype and genotype differences were
analyzed. Serotype 19A was more prevalent in Basque Country
than in Catalonia [21/90 (23.3%) vs 29/242; (12%) p = 0.01]
Table 1. Demographics, source of isolates and clinical
characteristics of IPD episodes.
1999–2000 2007–2009
n = 174 n = 335
age (mean6SD) 75.967.0 76.468.1
Male sex 100 57.5% 194 57.9%
Source of strains
Blood 150 86.2% 292 87.2%
CSF 9 5.2% 19 5.7%
Pleural fluid 12 6.9% 22 6.6%
Ascitic fluid 3 1.7% 2 0.6%
Clinical syndromes
Pneumonia 139 79.9% 269 80.3%
Meningitis 12 6.9% 28 8.4%
Peritonitis 8 4.6% 5 1.5%
Bacteremia without
focus
9 5.2% 20 6.0%
Septic arthritis 1 0.6% 1 0.3%
Otomastoiditis 1 0.6% 3 0.9%
Biliar 3 1.7% 3 0.9%
Cellulitis 0 0% 2 0.6%
No data 1 0.6% 4 1.2%
Main underlying diseases
COPD 40 23.0% 76 22.7%
Cirrhosis 15 8.6% 13 3.9%
Diabetes Mellitus 37 21.3% 80 23.9%
Malignance 39 22.4% 103 30.7%
Renal failure 7 4.0% 30 9.2%
doi:10.1371/journal.pone.0043619.t001
IPD in Older People in Spain
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whereas serotype 24F was only detected among pneumococci from
Catalonia [11/242 (4.5%) vs 0/90 (0%); p = 0.038]. These
differences were associated with genotype differences: two serotype
19A genotypes were only detected in the Basque Country (CC199
and ST193); and the prevalence of CC230 (which includes
serotype 24F and 19A) was more frequent in Catalonia [23/220
(10.5%) vs 3/85 (3.5%), p = 0.052].
Recent Changes in Serotypes and Genotypes
Figure 1 shows the serotype distribution in the two periods
analyzed: 1999–2000 (pre-PCV7) and 2007–2009 (pre-PCV13). In
the 2007–2009 period there was an overall decrease in the
frequency of PCV7 serotypes (4, 6B, 9V, 14, 18C, 19F and 23F),
from 45.4% (n = 79) to 18.4% (n = 61) (p,0.001). However, there
was an overall increase in the frequency of non-PCV7 serotypes
included in PCV13 (1, 3, 5, 7F, 6A and 19A), from 26.4% (n = 46)
in 1999–2000 to 41.0% (n = 136) in 2007–2009 (p = 0.001).
Serotype 19A increased from 2.0% in 1999–2000 to 15.1% in
2007–2009, a rise of 65.9% (95% CI, 16.9% to 203.8%). Two
serotypes not included in PCV13 increased in the 2007–2009
period: serotypes 6C (from 0% to 2.1%, p = 0.16) and 24F (from
0.6% to 3.3%, p = 0.066). No statistically significant differences in
serotype distribution were observed between patients aged 65–
74 years and those who were older (data not shown).
Figure 2 shows the overall (including isolates of both periods)
eBURST analysis of pneumococcal genotypes. A total of 22 clonal
groups and 46 singletons were found. The most frequent
genotypes among IPD episodes were: CC156 (n = 52, 11.2%),
CC260 (n = 38, 8.2%), ST191 (n = 28, 6.0%), CC230 (n = 27,
5.8%), ST247 (n = 20, 4.3%), CC53/62 (n = 19, 4.1%), CC30
(n = 17, 3.7%), ST306 (n = 17, 3.7%), CC180 (n = 16, 3.5%) and
ST433 (n = 15, 3.2%).
Table 3 shows the genotypes related to predominant serotypes
by period. Due to the low genetic diversity of some serotypes the
changes in the frequency of these serotypes was related to
genotype changes. For instance, the increase in serotype 1 was
associated with a significant increase in the ST306 clone (0.6% vs.
5.2%), while the increase in serotype 7F was related to the spread
of the ST191 clone (2.5% vs. 7.9%). The decrease in serotype 4
paralleled the decrease in ST247 (8.2% vs. 2.3%). The high
genetic diversity of other serotypes such as serotype 6C resulted in
no genotype-related changes. Finally, the changes in clonal
complexes (CC), which included isolates with different capsular
types, reflected the serotype increase or decrease on a different
scale. For instance, the multidrug-resistant CC230 increased
markedly (0.6% vs. 8.5%) because this CC includes STs of
serotypes 24F (ST230) and 19A (ST276 and ST2013), whose
frequency increased in the second period. Another example was
the decrease in CC156 (17.1% vs. 8.2%), which was related to the
decrease in serotypes 9V and 14.
It is interesting to note that despite the high genetic diversity of
serotype 19A, the alarming rise in this serotype was mainly
reflected in the increase of the previously mentioned CC230
(ST276 and ST2013; 0.6% vs. 5.6%) and three STs: ST1201
(0.6% vs. 3.3%), ST199 (0% vs. 2.6%) and ST193 (0% vs. 1.6%).
Discussion
Since the introduction of PCV7 for children important changes
in IPD have occurred in many countries. People over 65 are at
increased risk for developing IPD, mainly because of the ageing
process and associated co-morbidities. For these reasons pneumo-
coccal immunization has been recommended in this group of
patients [2]. Prior to 2011 only the 23-valent pneumococcal
polysaccharide vaccine was available for adult immunization, but
recently the pediatric conjugate vaccine with an enhanced
immunological response, PCV13, has been approved for adult
vaccination in Europe and the US. Knowledge of the current
serotype distribution of pneumococci causing IPD in adults over
65 would therefore be helpful in order to establish the current
coverage of this new vaccine in this age group.
In this way, three European regions recently replaced PCV7 for
PCV13 (Germany in December 2009, England and Wales in April
2010 and the Autonomous Region of Madrid in June 2010) in
routine childhood vaccination. In these regions an early effect of
reduction of IPD has been observed in children under 2 years
(target population). Moreover a reduction of IPD due to serotypes
19A and 7F has been demonstrated in England and Wales. These
preliminary data support the beneficial effect that could be
achieved after PCV13 vaccination of adults. [16,17,18].
In Spain the PCV7 vaccine for children was introduced in 2001
but it was not subsidized by the government, with exception of the
Autonomous Region of Madrid which started universal childhood
vaccination in November 2006 (more than 95% of children
vaccinated). Currently, in this Spanish region PCV7 serotypes
accounted for less than 5% of pediatric IPD episodes [16].
However, in the rest of the country, the use of PCV7 did increase
on a voluntary basis through the private sector, and childhood
vaccination rates (excluding the Madrid Region) are estimated to
be around 50–60% [4,10,11]. In agreement with other studies
carried out in countries where PCV7 has been used, we observed a
marked decrease in PCV7 serotypes among pneumococci causing
IPD in older adults due to herd protection [8,10–13]. Overall, a
major benefit of decreasing PCV7 serotypes was the fall in
antibiotic resistance. However, other non-PCV7 serotypes in-
creased, mainly due to clonal expansion [10,11,14,15,19,20]. For
instance, the rise in serotypes 1 and 7F in the 2007–2009 period
was associated with the clonal expansion of Sweden1-ST306 and
Netherlands7F-ST191, respectively, as observed during the first
decade of this century in most European countries [11,19–22].
However, the most notorious was the dramatic increase in
serotype 19A, as observed in many countries after PCV7
introduction, especially in children under 5 years of age
[4,6,11,12,23]. In our study, serotype 19A is currently the first
Table 2. Antimicrobial susceptibility of 335 invasive
pneumococci collected from adults $65 years old (2007–
2009).
MIC50 MIC90 %I %R
Antibiotic mg/ml
Penicillin (meningeal) #0.03 1 – 25.7
Penicillin (non- meningeal) #0.03 1 1.5 0
Penicillin (classical) #0.03 1 20.0 5.7
Cefotaxime (meningeal) #0.06 0.5 6.0 1.5
Cefotaxime (no-meningeal) #0.06 0.5 1.5 0
Erythromycin #0.5 $128 0 23.7
Clindamycin #0.25 $128 0 19.9
Tetracycline #0.25 32 6.4 16.8
Chloramphenicol #2 #2 – 6.4
Cotrimoxazol #0.5 $2 3.1 26.3
Ciprofloxacin 1 1 – 2.1
doi:10.1371/journal.pone.0043619.t002
IPD in Older People in Spain
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cause of invasive disease in older adults, as reported recently in
France; furthermore, and as described previously, serotype 19A
pneumococci were multiclonal [14,19,21]. The important role
acquired by serotype 19A makes it necessary to include this
serotype in the routine vaccination of older adults. Moreover,
multidrug resistance, which is frequent in this serotype, is related
Table 3. Distribution of genotypes associated with predominant serotypes by time period.






1 3 2 304 (n = 1), 306 (n = 1) 18 17 304 (n = 1); 306 (n = 16)
3 26 24 180 (n = 5); 260 (n = 15); 1220 (n = 3); 1253 (n = 1) 32 29 180 (n = 8); 260 (n = 15); 1220 (n = 4); 1253 (n = 2)
4 15 13 247(n = 13) 8 7 247 (n = 7)
6B 11 11 90 (n = 5); 315 (n = 3); 386 (n = 2); 490 (n = 1) 6 6 90 (n = 1); 138 (n = 1); 315 (n = 2); 1624 (n = 1); 386
(n = 1)
6C 0 0 – 7 6 224 (n = 3); 4011 (n = 1); 4310 (n = 1); 4534 (n = 1)
7F 5 4 191 (n = 4) 25 25 191 (n = 24), 4815 (n = 1)
8 9 8 53 (n = 7); 3219 (1) 9 8 53 (n = 5); 4816 (n = 1); 1629 (n = 2)
9V 14 14 66 (n = 1); 156 (n = 12); 280 (n = 1) 8 8 62 (n = 1); 156 (n = 5); 4796 (n = 1); 378 (n = 1)
14 20 19 17 (n = 4); 67 (n = 2); 156 (n = 12); 1554 (n = 1) 23 22 9 (n = 3); 67 (n = 1); 156 (n = 18)
16F 3 3 30 (n = 2); 4022 (n = 1) 15 14 30 (n = 12); 4022 (n = 1); 570 (n = 1)
19A 4 3 202 (n = 1); 276 (n = 1); 1201 (n = 1) 50 49 63 (n = 1); 81 (n = 1); 156 (n = 1); 193 (n = 5); 199 (n = 7);
202 (n = 1); 276 (n = 12); 320 (n = 3); 433 (n = 1); 645
(n = 1); 994 (n = 2); 1201 (n = 10); 2013 (n = 4)
19F 9 8 63 (n = 3); 88 (n = 1); 157 (n = 2); 177 (n = 2) 6 6 63 (n = 1); 88 (n = 3); 89 (n = 1); 177 (n = 1)
22F 5 5 433 (n = 4); 1372 (n = 1) 12 11 433 (n = 10); 3241 (n = 1)
24F 1 1 72 (n = 1) 11 11 230 (n = 10); 72 (n = 1)
12F 3 3 218 (n = 2); 4004 (n = 1) 9 6 989 (n = 6)
doi:10.1371/journal.pone.0043619.t003
Figure 1. Serotype distribution of invasive pneumococci collected from adults over 65 by period. The serotype distribution in the two
periods analyzed 1999–2000 (pre-PCV7, n = 174 isolates) and 2007–2009 (pre-PCV13, n = 332 isolates) is showed. Statistically significant changes are
indicated with an asterisk. Overall, PCV7 serotypes decreased from 45.4% (1999–2000) to 18.4% (2007–2009, p,0.001). Non-PCV7 serotypes included
in PCV13 increased from 26.4% to 41.0% (p= 0.001). Serotype 6A is not included in PPV23. In 2007–2009 period, the proportion of IPD isolates
included in PCV7 was 18.4%, with the proportions being 59.3% in PCV13 and 73.8% in PP23V.
doi:10.1371/journal.pone.0043619.g001
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to two clones: CC230 and CC320. CC320 is the major
contributor to the increase in resistant serotype 19A pneumococci
in the US and in Asia, but only 3 isolates from the present study
belonged to this CC [14,24,25]. Here, as in most other studies
from other European countries, the multidrug resistant strains are
mainly associated with ST276 or ST2013, which are single locus
and double locus variants of Denmark14-ST230 [18,25]. In fact,
CC230, which also includes isolates of serotype 24F with ST230,
ranks first among invasive isolates in the present study.
In 2010, PCV13 replaced PCV7 for child vaccination, and
PCV13 has recently been approved for adults. Given the results
obtained after PCV7 introduction one would expect to see a
progressive decrease in PCV13 serotypes among older adults over
the next few years. In fact, in the UK when the universal PCV13
vaccination started in April 2010 a decrease in PCV13 serotypes
(mainly 7F and 19A) has been observed in children and also in
adults by herd protection [17]. In this scenario, however, it is
important to know which serotypes could be prone to increase in
the near future. Our results showed an increase in serotype 24F
(non-PCV13) associated with the expansion of the ST230 clone,
which was described in Italy as a cause of meningitis [26].
However, this serotype-genotype association (24F-ST230) was
only detected in Catalonia. As regards serotype 6C, which
emerged in the 2007–2009 period accounting for 2.1% of invasive
isolates, the increase was multiclonal. Although serotype 6C is not
included in the current PCV13, cross-protection between
serotypes 6A and 6C has been reported [27]. Surveillance studies
are therefore needed in order to determine the impact of PCV13
on serotype 6C trends. The increases observed in other non-
PCV13 serotypes such as 22F, 12F, 16F and 35B may suggest that
these serotypes could play an important role in adult IPD in the
near future. In fact, serotypes 22F, 12F and 16F had low genetic
diversity thus the observed increase was due to a clonal expansion
(ST433, ST989, and CC30, respectively). Then, a surveillance of
these serotypes and genotypes should be performed to know the
impact of PCV13 introduction.
Regarding clinical manifestations we observed no important
changes, with pneumonia being the most common cause of IPD in
people over 65 and accounting for 80% of IPD episodes. Contrary
to what has been observed in children in our country, we found no
increase in empyema in these patients, probably because serotype
1 is less frequent in older adults than it is in children [22]. The
burden of IPD in older adults is an increasing problem in many
parts of the world, mainly due to the associated co-morbidities and
the increased life expectancy. In our study we observed no
significant changes in co-morbidities, with the exception of cancer,
which probably reflects the increased rate of cancer diagnoses
among the elderly.
Figure 2. Population structure of invasive S. pneumoniae collected from older people in Spain. The overall eBURST analysis of MLST data
for 463 invasive pneumococci showed 22 clonal groups and 46 singletons (blue lines: single locus variant; and pink lines: double locus variant). The
most frequent genotypes were: CC156 (11.2%), CC260 (8.2%), ST191 (6.0%), CC230 (5.8%), ST247 (4.3%), CC53/62 (4.1%), CC30 (3.7%), ST306 (3.7%),
CC180 (3.5%) and ST433 (3.2%).
doi:10.1371/journal.pone.0043619.g002
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The impact of child PCV7 vaccination on IPD in older adults
(herd protection) that has been demonstrated in the present study,
as well as by others, reinforces the relevance of adult vaccination
with conjugate vaccines [8,10–13]. In Europe, PCV10 and
PCV13 are currently used for children, and the latter has recently
been approved for adults over 50. Although we have not addressed
this study to adults 50–65, 64.7% of IPD occurred in people over
50 in 2007–2009 period in the three hospitals of the present study
were caused by serotypes included in PCV13. In the current
scenario, and given the efficacy of PCV7, the preliminary data of
PCV13 vaccination, and the coverage of PCV13 for adults over 65
(59.3%) or over 50 (64.7%), PCV13 could be a good vaccination
option for the elderly in Spain. However, this study is focused on
two Spanish regions and some regional differences have been
observed, therefore it is necessary to have local data in order to
establish the PCV13 coverage in each region. Finally, further




This study and publication of the results were approved by the
‘‘Comite´ E`tic d’Investigacio´ Clı´nica del Hospital Universitari de
Bellvitge’’ and written or oral informed consent was considered
not necessary, because data were analyzed anonymously.
Population and Invasive Disease Surveillance
We prospectively studied episodes of invasive pneumococcal
disease (IPD) diagnosed in adults $65 years in three Spanish
hospitals, two located in the region of Catalonia (Hospital
Universitari de Bellvitge and Hospital Universitari Germans Trias
i Pujol) and one in the Basque Country (Hospital Universitario
Donostia). IPD was defined as the presence of clinical symptoms
together with the growth of pneumococci in blood or other sterile
fluid samples (e.g., CSF, pleural fluid or ascitic fluid).
PCV7 was licensed for child vaccination in Spain in June 2001,
with PCV10 being licensed in April 2009 and PCV13 in June
2010. In order to identify changes in the serotype/genotype
distribution and emerging serotypes/clones not included in the
conjugate vaccines, two periods were compared: the current
distribution (2007–2009) and the distribution before the introduc-
tion of conjugate vaccines (1999–2000). Data concerning serotype
and genotype distributions for the 1999–2000 period have been
partially published [10,11].
Bacterial Srains, Serotyping and Antimicrobial
Susceptibility Tests
A total of 509 invasive pneumococci were analyzed from older
adults. Of these, 335 were collected in the 2007–2009 period and
174 in the 1999–2000 period. Serotype was determined by the
Quellung reaction and/or dot-blot assay or PCR in all 174 isolates
from the 1999–2000 period and in 332 (99.1%) isolates from the
2007–2009 period [28,29].
Antimicrobial susceptibility to penicillin, cefotaxime, erythro-
mycin, clindamycin, chloramphenicol and tetracycline were tested
by the microdilution method, following the procedures and criteria
of the Clinical Laboratory Standards Institute [30,31]. S.
pneumoniae ATCC 6303 and S. pneumoniae ATCC 49619 were used
as control strains.
Molecular Typing
A total of 463 (91.0%) available isolates were studied by pulsed-
field gel electrophoresis (PFGE) after Smal restriction [305 (91.1%)
from the 2007–2009 period and 158 (90.8%) isolated in the 1999–
2000 period] [32]. PFGE patterns were compared to representa-
tive international pneumococcal clones from the Pneumococcal
Molecular Epidemiology Network (PMEN) [32].
Selected isolates were studied by multilocus sequence typing
(MLST), as described previously [33]. These isolates were
representative of major PFGE clusters (those accounting for more
than 3 isolates). The allele number and sequence types (ST) were
assigned by using the pneumococcal MLST website (http://www.
mlst.net), which is hosted at Imperial College London and is
funded by the Wellcome Trust. When an unusual association
between serotype and sequence type was found, the serotype was




Statistical analyses were performed using SPSS for Windows,
version 17.0 (SPSS). We used X2 or Fisher’s exact tests to compare
proportions, as appropriate. A P value of ,0.05 was considered
statistically significant.
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